PAZINIB is a tyrosine kinase inhibitor that blocks proteins involved in tumour blood vessel formation and growth.
Recommended for:
Patients with metastatic renal cell carcinoma
Progressive soft tissue sarcomas
When standard chemotherapy fails
Need for targeted angiogenesis inhibition
Metastatic and advanced renal cell carcinoma
Soft tissue sarcomas (as second-line or further therapy)
PAZINIB should be taken orally on an empty stomach once daily. The tablet must not be crushed or broken. Dosage is determined individually by the treating oncologist.
Contraindications:
Hypersensitivity to pazopanib
Severe hepatic impairment
Pregnancy and breastfeeding
Side Effects:
Diarrhoea, hypertension
Nausea, fatigue
Elevated liver enzymes
Thrombocytopenia, skin rash